CRISPR Therapeutics AG
General ticker "CRSP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.2B (TTM average)
CRISPR Therapeutics AG follows the US Stock Market performance with the rate: 59.7%.
Estimated limits based on current volatility of 3.4%: low 52.92$, high 56.63$
Factors to consider:
- Total employees count: 393 as of 2024
- Top business risk factors: Insufficient funding, Gene editing technology risks, Supply chain disruptions, Geopolitical risks, Intellectual property risks
- Current price 17.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.99$, 49.70$]
- 2025-12-31 to 2026-12-31 estimated range: [12.97$, 34.86$]
Financial Metrics affecting the CRSP estimates:
- Negative: with PPE of -9.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.20 <= 0.33
- Positive: Shareholder equity ratio, % of 86.18 > 63.39
- Positive: -14.38 < Investing cash flow per share per price, % of -8.25
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CRSP quotes
Long-term CRSP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.44MM | $371.21MM | $35.00MM |
| Operating Expenses | $673.60MM | $593.74MM | $501.57MM |
| Operating Income | $-673.16MM | $-222.54MM | $-466.57MM |
| Non-Operating Income | $22.66MM | $71.82MM | $103.90MM |
| R&D Expense | $461.64MM | $387.33MM | $320.65MM |
| Income(Loss) | $-650.50MM | $-150.72MM | $-362.67MM |
| Taxes | $-0.33MM | $2.89MM | $3.59MM |
| Profit(Loss)* | $-650.17MM | $-153.61MM | $-366.25MM |
| Stockholders Equity | $1,875.48MM | $1,882.80MM | $1,932.08MM |
| Assets | $2,243.06MM | $2,229.57MM | $2,242.03MM |
| Operating Cash Flow | $-495.74MM | $-260.38MM | $-142.77MM |
| Capital expenditure | $37.19MM | $9.47MM | $1.90MM |
| Investing Cash Flow | $-258.65MM | $374.65MM | $-280.48MM |
| Financing Cash Flow | $38.59MM | $62.66MM | $331.98MM |
| Earnings Per Share** | $-8.36 | $-1.94 | $-4.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.